Edition:
United Kingdom

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.86USD
14 Dec 2018
Change (% chg)

$-0.24 (-4.71%)
Prev Close
$5.10
Open
$5.06
Day's High
$5.09
Day's Low
$4.84
Volume
254,246
Avg. Vol
211,787
52-wk High
$6.30
52-wk Low
$3.64

Latest Key Developments (Source: Significant Developments)

Inovio, Korean Partner Dose First Subject In Trial To Develop World's First Vaccine To Prevent Hepatitis C Infection
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO AND KOREAN PARTNER DOSE 1ST SUBJECT IN TRIAL TO DEVELOP WORLD'S FIRST VACCINE TO PREVENT HEPATITIS C INFECTION.  Full Article

Inovio Partners With Aids Malignancy Consortium To Advance Inovio’S HPV Therapy
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PARTNERS WITH AIDS MALIGNANCY CONSORTIUM TO ADVANCE INOVIO’S HPV THERAPY FOR HIGH-GRADE ANAL DYSPLASIA IN HIV-POSITIVE PATIENTS.INOVIO PHARMACEUTICALS INC - FINANCIAL DETAILS OF AGREEMENT WERE NOT DISCLOSED.INOVIO PHARMACEUTICALS - AMC WILL FUND PHASE 2 CLINICAL TRIAL TO EVALUATE EFFICACY OF VGX-3100 IN ADULT MEN AND WOMEN WITH HUMAN PAPILLOMAVIRUS (HPV)-RELATED HIGH-GRADE ANAL DYSPLASIA OR SQUAMOUS INTRAEPITHELIAL LESIONS (ASIL) AND HIV.  Full Article

Inovio Pharmaceuticals Reports Qtrly ‍Net Loss Attributable To Stockholders Of $0.24 Per Basic Share​
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS.Q4 REVENUE $8.8 MILLION VERSUS I/B/E/S VIEW $7.5 MILLION.QTRLY ‍NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $0.24 PER BASIC SHARE​.  Full Article

Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS.INOVIO PHARMACEUTICALS - UNDER AGREEMENT, PARKER INSTITUTE WILL HAVE RESPONSIBILITY FOR CLINICAL STUDY EXECUTION.INOVIO PHARMACEUTICALS - WILL PROVIDE FINANCIAL CONTRIBUTIONS IF CO'S PRODUCT(S) STUDIED UNDER COLLABORATION REACHES INITIATION OF PHASE 3 STUDY.  Full Article

Inovio Receives Milestone Payment From Medimmune
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2.  Full Article

Inovio Announces Analysis Of VGX-3100 Phase 2b Data
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Inovio Pharmaceuticals Inc ::INOVIO’S FURTHER ANALYSIS OF VGX-3100 PHASE 2B DATA REVEALS IMMUNE CORRELATES AND BIOMARKER SIGNATURES THAT PREDICTED CLINICAL EFFICACY.INOVIO PHARMACEUTICALS - ‍IN 2018, CO TO INITIATE PHASE 2 "PROOF-OF-CONCEPT" STUDY FOR TREATMENT OF HIGH GRADE ANAL NEOPLASIA.  Full Article

Inovio pharmaceuticals reports 2017 third quarter financial results
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Inovio Pharmaceuticals Inc :Inovio Pharmaceuticals reports 2017 third quarter financial results.Q3 loss per share $0.39.Q3 revenue $2.6 million versus $12.5 million.Q3 revenue view $9.4 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.Inovio Pharmaceuticals - ‍as of Sept 30, 2017, cash and cash equivalents and short-term investments were $141.9 million versus $104.8 million as of Dec 31, 2016​.  Full Article

Inovio Pharma says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Inovio Pharmaceuticals Inc :Inovio Pharmaceuticals says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14.Inovio Pharmaceuticals - Approval ‍included amendment to the $35 million payment co to receive from Apollobio as per agreement agreed between co, Apollobio.Inovio Pharmaceuticals says amendment was to reduce the purchase price of the $35 million payment from $8.20 to $7.22 per share - SEC Filing​.  Full Article

Inovio Pharmaceuticals qtrly loss per share $0.35
Wednesday, 15 Mar 2017 

Inovio Pharmaceuticals Inc : Inovio pharmaceuticals reports 2016 fourth quarter and year end financial results . Q4 revenue $8.5 million . Qtrly loss per share $0.35 .Q4 revenue view $5.9 million -- Thomson Reuters I/B/E/S.  Full Article

Inovio, Apollobio to develop and commercialize hpv pre-cancer immunotherapy VGX-3100 in Greater China
Monday, 13 Feb 2017 

Inovio Pharmaceuticals Inc : Inovio and Apollobio to collaborate on development and commercialization of hpv pre-cancer immunotherapy VGX-3100 in Greater China . Inovio Pharmaceuticals Inc - Inovio will receive $15 million in upfront and near term payments comprising an initial $3 million signing fee . Inovio Pharmaceuticals Inc - Inovio will receive a $12 million milestone upon lifting of VGX-3100 Phase 3 pre-initiation clinical hold by FDA . Inovio Pharmaceuticals Inc - under a separate equity agreement, Apollobio will invest in Inovio common stock subsequent to lifting of clinical hold . Inovio Pharmaceuticals Inc - aggregate investment, which is expected to be completed in first half of 2017, will not exceed $35 million . Inovio Pharmaceuticals Inc - Apollobio will fund all clinical development costs within licensed territory, and will pay Inovio up to $20 million . Inovio Pharma- agreements are subject to People's Republic of China corporate and regulatory approvals, payments are subject to PRC currency approvals .Inovio - payment of $20 million based upon achievement of certain regulatory milestones in U.S., China, Korea, double digit royalties on net sales of VGX-3100.  Full Article

Emergent-Valneva Zika vaccine clears early trial

Nov 19 A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.